Clinical trials: Antineoplastic Treatment
Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
This phase I/II trial studies the side effects and best dose of sapanisertib when given together with cabozantinib, and to see how well they work in treating patients with liver cancer that has spread from where it first started…
- Conditions
- Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT06811116
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Imaging Procedure
- Where
- 4 sites in United States
- Volunteers
- 92 people
- Sponsor
- National Cancer Institute (NCI)
Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
This clinical trial is looking at a drug called atezolizumab. Atezolizumab is approved as standard of care treatment for adult patients with urothelial cancer, non-small cell lung cancer, extensive-stage small cell lung cancer…
- Conditions
- Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT05770102)
- Testing
- Atezolizumab
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Urothelial Carcinoma, Urothelial Carcinoma Recurrent
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in the United States.
- Conditions
- Urothelial Carcinoma, Urothelial Carcinoma Recurrent, Urothelial Carcinoma Ureter, Urothelial Carcinoma Ureter Recurrent
- Trial name
- uTRACT (NCT05874921)
- Testing
- Jelmyto (mitomycin) for pyelocalyceal solution
- Where
- 22 sites in United States
- Volunteers
- 450 people
- Sponsor
- UroGen Pharma Ltd.
Breast Neoplasms, Breast Cancer
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
This study will look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast cancer.
- Conditions
- Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
- Trial name
- NCT05113251
- Testing
- Trastuzumab Deruxtecan, Paclitaxel, Trastuzumab
- Where
- 145 sites in United States, Brazil and 16 more
- Volunteers
- 927 people
- Sponsor
- AstraZeneca
Oral Mucositis (Ulcerative) Due to Antineoplastic Therapy
Prevention of Oral Mucositis After Using Chamomile Oral Cryotherapy Versus Oral Cryotherapy in Pediatric Cancer Patients Receiving Chemotherapy.
oral mucositis is a painful situation that significantly affects patients' quality of life with the severe cases being associated with ulcerated mucosa and secondary infection which may lead to life-threatening sepsis.Chamomile…
- Trial name
- NCT03605186
- Testing
- Chamomile oral cryotherapy, Oral cryotherapy
- Where
- Egypt
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Cairo University
Cancer, Adherence to Medication Regime
Mobile Application to Assist Adherence to Oral Anticancer Agents and Symptom Management
The use of oral anticancer agents (OAAs) in cancer treatment has increased especially in the last two decades. The use of mobile health technologies in the management of OAA can be beneficial in terms of treatment adherence and…
- Conditions
- Cancer, Adherence to Medication Regime, Symptom Management
- Trial name
- NCT04626830
- Testing
- Mobile Application Intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Baskent University
Metastatic Colorectal Cancer (CRC), Antineoplastic Agents, Immunological
Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer
The main objective of this study is to identify the prognostic factors (clinico-biological) for the efficacy (overall survival) of fruquintinib in patients with metastatic colorectal cancer.
- Conditions
- Metastatic Colorectal Cancer (CRC), Antineoplastic Agents, Immunological, VEGFR-TKI
- Trial name
- COFRUQ (NCT07124858)
- Testing
- Fruquintinib
- Where
- 83 sites in France
- Volunteers
- 300 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Brain and Central Nervous System Tumors
A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma
The primary objective of this study is to evaluate the safety, efficacy and clinical activity of Pamiparib in combination with radiation therapy (RT) and/or temozolomide (TMZ) in participants with newly diagnosed or…
- Trial name
- NCT03150862
- Testing
- Pamiparib, TMZ, Radiation
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 116 people
- Sponsor
- BeiGene USA, Inc.
Solid Tumor
A MolEcularly Guided Anti-Cancer Drug Off-Label Trial
This is a prospective, open-label, non-randomized combined basket- and umbrella trial divided in two parts; a limited feasibility-oriented part 1 including 154 patients and 3 treatment cohorts and part 2 that will include an…
- Trial name
- MEGALiT (NCT04185831)
- Testing
- Atezolizumab, Everolimus, Cobimetinib
- Where
- 3 sites in Sweden
- Volunteers
- 167 people
- Sponsor
- Uppsala University Hospital
Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
This first-in-human study evaluates safety, tolerability and distribution of [225Ac] FPI-1966, [111In]-FPI-1967, and vofatamab in patients with FGFR3-expressing solid tumors.
- Conditions
- Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma, Susceptible FGFR3 Genetic Alterations
- Trial name
- NCT05363605
- Testing
- [225Ac]-FPI-1966, [111In]-FPI-1967, vofatamab
- Where
- 6 sites in United States, Australia
- Volunteers
- 6 people
- Sponsor
- Fusion Pharmaceuticals Inc.
Neoplasms
A Study of ADH300004 in Surgically Resected Primary or Metastatic Colorectal Cancer and Liver Biopsy, or Planned Hepatic Resection
5 fluorouracil (5 FU), one of the most actively investigated anti-cancer drugs, is rapidly inactivated by the enzyme dihydropyrimidine dehydrogenase (DPD). ADH300004 blocks DPD.
- Trial name
- NCT00264446
- Testing
- ADH300004
- Where
- United States
- Sponsor
- Adherex Technologies, Inc.
Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
This phase III trial compares the effect of adding gemcitabine to intravesical Bacillus Calmette Guerin (BCG) versus intravesical BCG alone in patients with non-muscle invasive bladder cancer that has come back after a period of…
- Conditions
- Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
- Trial name
- GAIN-BCG (NCT07000084)
- Testing
- BCG Solution, Biopsy of Bladder, Cystoscopy
- Where
- 60 sites in United States
- Volunteers
- 330 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-Muscle Invasive Bladder Cancer (NMIBC)
Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment
A Phase Ib, open label, non randomized study to measure the safety and PK characteristics of APL-1202 at steady-state in adult male and female BCG resistant NMIBC patients when it is administered alone and concurrently with BCG.
- Trial name
- NMIBC (NCT03672240)
- Testing
- APL-1202
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Asieris Pharmaceutical Technologies Co., Ltd.
Ovarian Cancer, Organoid
Study on the Consistency Evaluation of Organoids Used in the Clinical Treatment of Ovarian Cancer With Anti-tumor Drugs
This is a single-center, observational clinical study that plans to recruit 64 ovarian cancer patients within one year. The purpose of this study is to evaluate the consistency and accuracy of the organoid model derived from…
- Trial name
- NCT05175326
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hepatocellular Carcinoma, Liver Neoplasms
TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC
Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death that ranks sixth in terms of incident cases, with an overall 5 years survival of 18%.
- Conditions
- Hepatocellular Carcinoma, Liver Neoplasms, Digestive System Neoplasms, Sorafenib
- Trial name
- NCT04518852
- Testing
- TACE combined with sorafenib and PD-1 mAb
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Breast Neoplasm, Breast Cancer
Effect of a Clinical Nutrition Intervention Program in Breast Cancer Patients During Antineoplastic Treatment
The aim of this study is to evaluate the effect of a 6-mo individualized and specialized food-based nutrition intervention program in breast cancer patients' body composition, metabolism and antioxidant activity associated with…
- Trial name
- NCT03625635
- Testing
- Individualized food-based intervention
- Where
- Mexico
- Volunteers
- 34 people
- Sponsor
- Humberto Francisco Astiazaran Garcia, PhD
Brest Cancer, Abemaciclib
Retrospective Observational Study of the Safety and Toxicity Management of Abemaciclib in Combination with Adjuvant Hormone Therapy in Patients with RH+ ,HER2-nonoveramplified Breast Cancer, Real-life Data (MONARCHE29)
Overall survival at 8 years under treatment for localized hormone-dependent breast cancer is 93.3% (1). Adjuvant therapy, especially hormone therapy, helps reduce the risk of recurrence.
- Conditions
- Brest Cancer, Abemaciclib, Adjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols
- Trial name
- MONARCHE29 (NCT06621459)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Brest
Amyloidosis
Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis
In this study, the investigators seek to evaluate bone marrow and blood samples and treatment responses to see if Minimal Residual Disease (MRD) can be used as a predictive method of response to treatment in amyloidosis.
- Trial name
- MRD (NCT02716103)
- Testing
- blood collection, bone marrow collection
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Boston Medical Center
Endometrial Neoplasms, Ovarian Neoplasms
A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers
This phase 1b/2a study evaluates the investigational oral drug catequentinib hydrochloride (AL3818), given alone or with AL58805, temozolomide, or lomustine (CCNU), in adults with advanced or metastatic solid tumors.
- Conditions
- Endometrial Neoplasms, Ovarian Neoplasms, Soft Tissue Sarcoma (STS), Glioblastoma
- Trial name
- NCT07811297
- Testing
- AL58805, AL3818, Temozolomide (TMZ)
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- Advenchen Pharmaceuticals, LLC.
Oral Mucositis (Ulcerative), Oral Mucositis (Ulcerative) Due to Radiation
Photobiomodulation to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Head & Neck Cancer Patients
The overall purpose of this clinical study is to evaluate safety and efficacy of the MuReva Phototherapy System with a light delivery mouthpiece to reduce the severity of oral mucositis (OM) in adult patients with squamous cell…
- Conditions
- Oral Mucositis (Ulcerative), Oral Mucositis (Ulcerative) Due to Radiation, Oral Mucositis (Ulcerative) Due to Antineoplastic Therapy, Head and Neck Cancer
- Trial name
- NCT03972527
- Testing
- Photobiomodulation, Routine Oral Care and Analgesia
- Where
- 12 sites in United States
- Volunteers
- 85 people
- Sponsor
- MuReva Phototherapy Inc.